Charcot Foot Reconstruction Market To Reach $283.2 Million By 2030

Charcot Foot Reconstruction Market Growth & Trends

The global charcot foot reconstruction market size is expected to reach USD 283.2 million by 2030, registering a CAGR of 4.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market growth is driven by the rising prevalence of diabetes especially among the aging population. Factors such as the growing patient preference for mobility as well as the awareness and diagnosis of Charcot foot reconstruction surgeries are anticipated to further fuel the growth. In addition, the manufacturers are involved in strategic initiatives such as gaining approvals and launching new & innovative products for diabetic care. For instance, in July 2022, Orp yx Medical Technologies Inc. launched its Orphyx remote monitoring services, extending mobility for diabetic patients factors are likely to drive the market over the forecast period.

Rising prevalence of diabetes-related foot diseases such as Charcot neuroarthropathy and diabetic foot ulcers is on the rise. These diseases levy a substantial financial burden on the country’s healthcare system. For instance, in the U.S., diabetic foot ulcer care amounts to approximately USD 130 billion annually. The American Podiatric Medical Association (APMA) states that diabetic foot ulcers are open sores or wounds affecting around 15% of diabetes patients, typically found on the foot's underside. In addition, according to studies published in the Journal of Clinical Endocrinology, people with type 1 diabetes are found to be more prone to have Charcot neuroarthropathy. Diabetic ulcers and diabetic foot disease necessitate extensive self-care from patients, involving daily wound management.

Presence of government funding programs across various observational studies aimed at reducing the burden of diabetic foot diseases, by introducing various cohort studies, is expected to have a positive impact on the market. Recently, in October 2023, a study on ‘Prevalence Of Charcot Foot In The Patient With Diabetes’ was funded by the Swedish Research Council, Stockholm County Research Council, the study further aimed at comparing the results for CF between type 1 and type 2 diabetes patients. The study concluded that the prevalence of CF was larger across subjects with type 1 diabetes. In addition, the incorporation of minimally invasive surgical approaches, and novel biomaterials, coupled with technological advancements such as personalized diabetic ulcer patches (3C Patch) from Reapplix is expected to boost market growth. For instance, in February 2023, Northwestern University researchers developed novel transient electronic patches and bioresorbable bandages that fastens the wound healing by 30%. Such developments are poised for market growth.

The key market players are aopting strategic initiatives to expand their business footprint and grow their clientele. For instance, in December 2022, Arthrex.INc, launched a new patient-focused resource, as ‘TheNanoExperience.com’, which will create awareness amongst patients and provide surgeons with the usage scope for minimally invasive devices.

 Request a free sample copy or view report summary: Charcot Foot Reconstruction Market Report

Charcot Foot Reconstruction Market Report Highlights

• Based on product, the foot plating systems segment dominated the market in 2023. Foot plating systems are specialized surgical tools and techniques used to stabilize and repair the damaged structures within the foot. These systems often involve the use of metal or synthetic plates and screws to secure bones in their proper positions, allowing for better healing and recovery from the complications of Charcot foot.

• Based on fixation, the external fixation systems segment is expected to grow at the fastest CAGR of 5.7% over the forecast period. This can be attributed to the external fixator enabling proper healing and reducing the risk of complications, with maintaining the foot's stability and alignment, Individualized treatment is crucial for patients with Charcot foot deformities. For complex reconstructions in severely deformed feet, a combined internal and external fixation technique is often preferred. This method involves using both metal or synthetic plates & screws to secure bones & circular fixators to stabilize adjacent joints if necessary. This comprehensive approach ensures better support & stability during the reconstruction & healing process.

• North America dominated the global market in 2023, due to the presence of a large number of major market players, government involvement in rising awareness about diabetic foot, launch of diverse range of products and procedures aimed at restoring stability and functionality.

Charcot Foot Reconstruction Market Segmentation

Grand View Research has segmented the global Charcot foot reconstruction market based on product, fixation type, application, end-user, and region:

Charcot Foot Reconstruction Product Type Outlook (Revenue, USD Million, 2018 - 2030)

• Implants

• Foot Plating Systems

• Nail system

• External Fixation Systems

• Others

Charcot Foot Reconstruction Fixation Type Outlook (Revenue, USD Million, 2018 - 2030)

• External

• Internal

Charcot Foot Reconstruction Application Outlook (Revenue, USD Million, 2018 - 2030)

• Forefoot

• Mid foot

• Hind foot

• Ankle

Charcot Foot Reconstruction End-user Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital

• Outpatient Facilities

Charcot Foot Reconstruction Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Mexico

  • Argentina

• MEA

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Charcot Foot Reconstruction Market:

• Stryker

• Zimmer Biomet

• DePuy Synthes

• Arthrex Inc.

• Orthofix

• Acumed LLC

• Integra LifeSciences

• Ossur

• DJO LLC

• Paragon 28 Inc.